Respiratory Syncytial Virus Diagnostics Market Report by Product, End Use, and Region 2024-2032
세계의 호흡기 세포융합 바이러스(RSV) 진단 시장 규모는 2023년 10억 520만 달러에 달했습니다. 향후 IMARC 그룹은 2024년부터 2032년까지의 성장률(CAGR)은 8.1%를 보이며, 2032년에는 20억 7,230만 달러에 달할 것으로 예측했습니다.
호흡기 세포융합 바이러스(RSV)는 폐와 호흡기의 바이러스 감염으로 천식, 입원, 폐렴, 반복 감염, 중이염, 사망의 원인이 됩니다. 혈액 검사, 흉부 X선 검사, 분비물의 봉제 검사, 펄스 옥시메트리 등을 이용하여 폐 염증, 백혈구 수, 혈중 산소 농도 등의 징후를 확인하여 진단할 수 있습니다. RSV의 일반적인 치료법으로는 시판약, 점적, 가습산소, 인공호흡, 흡입 기관지 확장제 등이 있습니다.
호흡기 세포융합 바이러스(RSV) 진단 약물 시장 동향 :
RSV 감염은 2세 미만의 어린이가 심각한 호흡기 증상을 일으키는 경향이 있기 때문에 신생아기에 심각해질 수 있습니다. 이것은 자녀의 의료에 대한 부모의 관심이 증가함에 따라 시장 성장을 가속하는 중요한 요소 중 하나입니다. 또한 조기 진단 후 생존율의 높이와 진단 수단의 입수 용이성도 성장을 가속하는 요인이 되고 있습니다. 이 외에도 건강 관리 인프라 개선 및 입원 유아의 치료에 대한 유리한 상환 정책도 시장 성장에 기여합니다. 게다가, 생명공학과 나노기술과 같은 첨단기술의 출현은 웨스턴 블롯, 효소 결합 면역흡착 측정법(ELISA), 직접 면역형광법, 실시간 중합효소 연쇄반응(PCR)과 같은 RSV의 최신 검출 시스템 개발을 촉진합니다. 이 외에 각국의 정부기관이 새로운 치료제의 개발을 위한 연구개발(R&D) 프로젝트에 자금을 제공합니다. 시장을 견인할 것으로 예상되는 기타 요인으로는 임상백신시험 증가, 체외진단에 대한 수요 증가, 소아폐렴 발생률 상승, 분자진단 채용 증가 등이 있습니다.
이 보고서에서 다루는 주요 질문
- 세계의 호흡기 세포융합 바이러스(RSV) 진단 시장은 지금까지 어떻게 추이해 왔는가?
- COVID-19가 세계의 호흡기 세포융합 바이러스(RSV) 진단 시장에 미친 영향은?
- 주요 지역 시장은?
- 제품별 시장 분석은?
- 최종 용도별 시장 분석은?
- 업계의 밸류체인의 다양한 단계란?
- 업계의 주요 촉진요인과 도전은 무엇인가?
- 세계의 호흡기 세포융합 바이러스(RSV) 진단 약물 시장의 구조와 주요 기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계 호흡기 세포융합 바이러스(RSV) 진단 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 제품별
- 직접 형광 항체법(DFA)
- 신속 항원 진단 검사(RADT)
- 분자진단
- 크로마토그래피 면역 측정법
- 진단 이미지
- 겔 마이크로드롭렛
- 플로우 사이토메트리
- 기타
제7장 시장 내역: 최종 용도별
제8장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Becton, Dickinson and Company
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- Coris BioConcept
- DiaSorin Molecular LLC(DiaSorin Inc)
- F. Hoffmann-La Roche AG
- Merck KGaA
- Quest Diagnostics Incorporated
- Quidel Corporation
- Thermo Fisher Scientific Inc.
JHS
The global respiratory syncytial virus (RSV) diagnostics market size reached US$ 1,005.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,072.3 Million by 2032 exhibiting a growth rate (CAGR) of 8.1% during 2024-2032.
Respiratory syncytial virus (RSV) is a viral infection of the lungs and respiratory tract, which can cause asthma, hospitalization, pneumonia, repeated infections, middle ear infection, and death. It can be diagnosed using blood tests, chest x-rays, a swab of secretions, and pulse oximetry by checking for signs like lung inflammation, white blood cell (WBC) count, and oxygen levels in the blood. Some of the commonly available treatment options for RSV are over-the-counter (OTC) medications, intravenous (IV) fluids, humidified oxygen, mechanical ventilation, and inhaled bronchodilators.
Respiratory Syncytial Virus (RSV) Diagnostics Market Trends:
RSV infection can be more serious during the neonatal period as children under two years of age tend to develop severe respiratory symptoms. This, in confluence with the rising focus of parents on child medical care, represents one of the crucial factors fostering the growth of the market. Moreover, the high survival rates after early diagnosis and the easy availability of diagnostic modalities act as other growth-inducing factors. Apart from this, the improving healthcare infrastructure and favorable reimbursement policies for the treatment of hospitalized infants are also contributing to market growth. Furthermore, the advent of advanced techniques like bio- and nanotechnology is facilitating the development of modern detection systems for RSV, such as western blot, enzyme-linked immunosorbent assay (ELISA), direct immunofluorescence, and real-time polymerase chain reaction (PCR). Besides this, governing agencies of numerous countries are funding research and development (R&D) projects for the development of new therapeutics. Other factors projected to drive the market are the growing number of clinical vaccine trials, the escalating demand for in-vitro diagnostics, rising incidences of childhood pneumonia and the increasing adoption of molecular diagnostics.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global respiratory syncytial virus (RSV) diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and end use.
Breakup by Product:
Direct Fluorescent Antibody (DFA) Method
Rapid Antigen Diagnostic Test (RADTs)
Molecular Diagnostics
Chromatographic Immunoassay
Diagnostic Imaging
Gel Microdroplets
Flow Cytometry
Others
Breakup by End Use:
Hospitals and Clinics
Laboratory
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., Coris BioConcept, DiaSorin Molecular LLC (DiaSorin Inc), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics Incorporated, Quidel Corporation and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
- How has the global respiratory syncytial virus (RSV) diagnostics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global respiratory syncytial virus (RSV) diagnostics market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global respiratory syncytial virus (RSV) diagnostics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Respiratory Syncytial Virus (RSV) Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Direct Fluorescent Antibody (DFA) Method
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Rapid Antigen Diagnostic Test (RADTs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Molecular Diagnostics
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Chromatographic Immunoassay
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Diagnostic Imaging
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Gel Microdroplets
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Flow Cytometry
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by End Use
- 7.1 Hospitals and Clinics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Laboratory
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Becton, Dickinson and Company
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 bioMerieux SA
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Bio-Rad Laboratories Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Coris BioConcept
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 DiaSorin Molecular LLC (DiaSorin Inc)
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 F. Hoffmann-La Roche AG
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 SWOT Analysis
- 13.3.8 Merck KGaA
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Quest Diagnostics Incorporated
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Quidel Corporation
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Thermo Fisher Scientific Inc.
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
- 13.3.11.3 Financials
- 13.3.11.4 SWOT Analysis
